There are few pathological descriptions of the healing phase ... sequelae of respiratory distress syndrome described here also resemble, to a small extent, the findings in cystic fibrosis of ...
Financing led by Velan Capital with participation from new and existing healthcare-focused institutional investors and insidersCapital raise to ...
Edesa anticipates topline results could be available within as few as 12 to 18 months following regulatory clearance by the FDA. Health Canada has previously granted approval to initiate this Phase 2 ...
TORONTO - Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has announced the completion of a private placement funding round on February 12, 2025, raising approximately ...
They are observed in ARDS, are especially covering denuded basement membranes where pneumocytes are missing, and may be related to adverse outcome (56). Endocytosis of macromolecules can be mediated ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
A discovery offers new hope in the battle against pulmonary fibrosis, a debilitating lung condition that progressively makes it harder for patients to breathe. Scientists have pinpointed proteins in ...
Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback